Home >> Allergy/Immunology >> Allergy/Immunology >> Baby Food >> Technology & Media >>

Cardiac Fibrosis - Pipeline Review, H1 2013

Published: Apr-2013 | Format: PDF | Global Markets Direct | Number of pages: 36 | Code: MRS - 977

Global Markets Direct’s, 'Cardiac Fibrosis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cardiac Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cardiac Fibrosis. 

Cardiac Fibrosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

A snapshot of the global therapeutic scenario for Cardiac Fibrosis.
A review of the Cardiac Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of products based on various stages of development ranging from discovery till registration stages.
A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Coverage of the Cardiac Fibrosis pipeline on the basis of route of administration and molecule type.
Key discontinued pipeline projects.
Latest news and deals relating to the products.

Reasons to buy

Identify and understand important and diverse types of therapeutics under development for Cardiac Fibrosis.
Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
Devise corrective measures for pipeline projects by understanding Cardiac Fibrosis pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Introduction
Global Markets Direct Report Coverage
Cardiac Fibrosis Overview
Therapeutics Development
An Overview of Pipeline Products for Cardiac Fibrosis
Cardiac Fibrosis Therapeutics under Development by Companies
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Cardiac Fibrosis Therapeutics – Products under Development by Companies
Companies Involved in Cardiac Fibrosis Therapeutics Development
Merck & Co., Inc.
BioLineRx, Ltd.
Digna Biotech, S.L.
miRagen Therapeutics, Inc.
Fibrotech Therapeutics Pty. Ltd.
Cardiac Fibrosis – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
P-17 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
disitertide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CGEN-856 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MGN-4220 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FT-011 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CARD-024 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cardiac Fibrosis Therapeutics – Drug Profile Updates
Cardiac Fibrosis Therapeutics - Dormant Products

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products Under Development for Cardiac Fibrosis, H1 2013
Products under Development for Cardiac Fibrosis – Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013
Comparative Analysis by Early Clinical Stage Development, H1 2013
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013
Products under Development by Companies, H1 2013
Merck & Co., Inc., H1 2013
BioLineRx, Ltd., H1 2013
Digna Biotech, S.L., H1 2013
miRagen Therapeutics, Inc., H1 2013
Fibrotech Therapeutics Pty. Ltd., H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Stage and Molecule Type, H1 2013
Cardiac Fibrosis Therapeutics – Drug Profile Updates
Cardiac Fibrosis Therapeutics – Dormant Products

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing